Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

completed375%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

NCT06762600
completedphase_2

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

NCT05966272
completedphase_2

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

NCT05881837
unknownphase_2

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

NCT06054698

Clinical Trials (4)

Showing 4 of 4 trials
NCT06762600Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

Completed
NCT05966272Phase 2

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

Completed
NCT05881837Phase 2

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Completed
NCT06054698Phase 2

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4